Get the Stockscreener App
0.687
6.56%
-0.0482
Pre-market:
.69
0.003
+0.44%
Neurosense Therapeutics Ltd stock is traded at $0.687, with a volume of 296.66K.
It is down -6.56% in the last 24 hours and down -16.89% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$0.7352
Open:
$0.75
24h Volume:
296.66K
Relative Volume:
1.94
Market Cap:
$24.80M
Revenue:
-
Net Income/Loss:
$-10.21M
P/E Ratio:
-1.176
EPS:
-0.5842
Net Cash Flow:
-
1W Performance:
-8.59%
1M Performance:
-16.89%
6M Performance:
-18.07%
1Y Performance:
-71.13%
1-Day Range:
$0.6701
$0.77
1-Week Range:
$0.6701
$0.8171
52-Week Range:
$0.63
$2.5199
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.687 | 24.80M | 0 | -10.21M | 0 | -0.5842 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
NRSN Q1'26 Earnings: revenue estimate is 514.10K USD - TradingView
NeuroSense Therapeutics Ltd. (NRSN) Q2 2025 Earnings: Narrower-than-Expected Loss Marks Progress Amid Clinical-Stage OperationsEarnings Yield Analysis - newsline.com
NeuroSense Secures South Korean Patent for ALS Drug Candidate PrimeC - TipRanks
NeuroSense (Nasdaq: NRSN) secures South Korean patent protection for ALS therapy PrimeC - Stock Titan
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS - PR Newswire
Roth MKM Maintains NeuroSense Therapeutics(NRSN.US) With Buy Rating, Maintains Target Price $3 - Moomoo
NeuroSense Therapeutics Wins Key Japanese Patent for ALS Drug PrimeC - TipRanks
Japanese patent extends PrimeC protection to 2042 for NeuroSense (NRSN) - Stock Titan
Japan grants 2042 patent on ALS drug combo: NeuroSense's PrimeC - Stock Titan
Neurosense Therapeutics Ltd (NASDAQ: NRSN) Share Price, NRSN Stock News, NRSN Share Price & Updates - Kalkine
NeuroSense Therapeutics Advances Canadian Regulatory Talks on ALS Drug PrimeC - TipRanks
NeuroSense (NRSN) advances Health Canada discussions on PrimeC ALS regulatory path - Stock Titan
NRSN Q2 2025 Earnings: EPS Beat Signals Progress Amid Development StageFinancial Health Score - newsline.com
NRSN Q2 2025 Earnings: Narrower-than-Expected Loss Fails to Lift SharesDividend Increase Stocks - The Legal Advocate
NeuroSense Therapeutics (NRSN) Faces 4.5% Decline—Key Support at $0.78 Holds the LinePrice Action Signals - The Legal Advocate
NeuroSense Therapeutics (NRSN) Slides 3.94%, Pivots Near Key Support at $0.82VWAP Deviation - newsline.com
NeuroSense Therapeutics (NRSN) Edges Higher, Testing Resistance at $0.95PCR Moving Average - The Legal Advocate
NeuroSense trades close to 90 cents as next $1 Nasdaq threshold comes into view - Bez Kabli
Amyotrophic Lateral Sclerosis (ALS) Market Set for Significant - openPR.com
NRSN Q2 2025 Earnings: Narrower Loss Surprises, Shares Gain on Cost DisciplineFinal Results - The Legal Advocate
NeuroSense Therapeutics (NRSN) Slides 4.56% as Support Levels Are TestedExpert Market Insights - Newser
OutSee Selected for Discovery Award from Longitude Prize on ALS to Accelerate AI-Based Target Discovery - Yahoo Finance
TradingKey - TradingKey
NRSN (NeuroSense Therapeutics) Q2 loss narrows 6.9% more than expected, but investors await pipeline catalyst update.Expert Verified Trades - newser.com
NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price - The Globe and Mail
NeuroSense Announces Pricing of Insider-Led PIPE Financing - The Malaysian Reserve
NeuroSense (Nasdaq: NRSN) insiders lead $600K PIPE financing at premium - Stock Titan
NeuroSense Therapeutics Ltd. announced that it expects to receive $0.6 million in funding - marketscreener.com
NeuroSense Therapeutics Transitions Chief Medical Officer to Advisory Role Ahead of Key PrimeC Milestones - The Globe and Mail
NeuroSense (NRSN) CMO steps down but stays on as advisor for PrimeC - Stock Titan
Niva Russek Blum Net Worth (2026) - GuruFocus
Ferenc Tracik Net Worth (2026) - GuruFocus
Hagit Binder Net Worth (2026) - GuruFocus
Alon Ben Noon Net Worth (2026) - GuruFocus
Revital Mandil Levin Net Worth (2026) - GuruFocus
Tangible book value per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
EBIT per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Operating cash flow per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
NEUROSENSE THERAPEUTICS LTD (NRSN) Earnings History & Surprises - ChartMill
Form 20-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)] - ADVFN
Sentiment Review: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesPortfolio Gains Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
Nasdaq Moves: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingPortfolio Value Report & Real-Time Sentiment Analysis - baoquankhu1.vn
Patterns Watch: Is NeuroSense Therapeutics Ltd Equity Warrant part of any ETF2026 Top Decliners & Real-Time Price Movement Reports - baoquankhu1.vn
If You Invested $1,000 in Neurosense Therapeutics Ltd (NRSN) - Stock Titan
Trend Report: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingWeekly Risk Report & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Bank Watch: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingMarket Weekly Review & Daily Stock Trend Reports - baoquankhu1.vn
Chipmakers Recap: Why is NeuroSense Therapeutics Ltd stock going downEarnings Growth Summary & Weekly Market Pulse Alerts - baoquankhu1.vn
Aug Highlights: What are NeuroSense Therapeutics Ltd Equity Warrants earnings expectations2026 Earnings Surprises & Low Risk Entry Point Tips - baoquankhu1.vn
NRSN Analyst Rating Update: D. Boral Capital Maintains 'Buy' Rat - GuruFocus
Inflation Data: Is NeuroSense Therapeutics Ltd Equity Warrant stock undervalued right nowEarnings Summary Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Volatility Watch: Can NeuroSense Therapeutics Ltd Equity Warrant keep up with sector leaders2026 Price Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):